Home Database Healthcare & PharmaPatterson Companies

04/2025100%

Patterson Companies acquired by Patient Square Capital

UNITED STATES Life Sciences / Medical Devices / Medical Consumables EV $1–10bn

Context

Patient Square Capital completed the acquisition of 100% of Patterson Companies, taking the business private and delisting it from the NASDAQ Global Select Market. Patterson will maintain its headquarters in St. Paul, Minnesota. The transaction positions Patterson to accelerate its growth strategy and strengthen its offering to dental and animal health customers under Patient Square's healthcare-focused ownership and operational support.

Patterson Companies, which reported an EBITDA margin of [members only] in 2024, is valued in this transaction at an EV/EBITDA multiple of 5x–12x, representing a discount to the average observed in the Healthcare & Pharma sector (14.5x in 2025).

-> Deep-dive in Healthcare & Pharma market trends

Target

Patterson Companies is a leading US-based distributor of products and services to two distinct end markets: (1) dental, providing dental practitioners and laboratories across North America and the UK with consumables, equipment, technology solutions, and value-added services; and (2) animal health, supplying veterinary practices and production animal operations through its Animal Health International subsidiary. The company operates a comprehensive portfolio combining product distribution with proprietary software, digital solutions, and practice management services, supported by an extensive logistics and supply chain network across North America and the UK.

Ent. Value

$1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

below 1.5x

EV / EBITDA

5x–12x

EV / EBIT

[members only]

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with Patient Square Capital

Other operations with Patient Square Capital
Date	Acquirer	Target	Country	Sector
04/2022	PATIENT SQUARE CAPITAL	SOC TELEMED	UNITED STATES	Healthcare

Similar deals in Life Sciences

Similar deals in Life Sciences
Date	Acquirer	Target	Country	Sector
05/2025	OTTOBOCK	MATTON ORTHOMEDI	BELGIUM	Implants & Prosthetics
05/2025	IK PARTNERS	BIOBANK	FRANCE	Implants & Prosthetics
04/2025	NORGINE	THERAVIA	FRANCE	Generics / Labs
04/2025	CINVEN	NUTRISENS	FRANCE	Nutrition & Dietary Supplements
04/2025	KNOP INVESTMENTS	AVANCE CARE GROUP	NETHERLANDS	Medical Devices
04/2025	INSTITUT MERIEUX / ARCHIMED	CEVA SANTE ANIMALE	FRANCE	Animal Health
04/2025	IK PARTNERS	STERIMED	FRANCE	Medical Consumables
03/2025	NUTRISENS	PRODIET	BRAZIL	Nutrition & Dietary Supplements
03/2025	ZYDUS	AMPLITUDE SURGICAL	FRANCE	Implants & Prosthetics
03/2025	SIPAREX	LABORATOIRE POLIDIS	FRANCE	Medical Consumables

REFERENCES

Valuation range: EV $1–10bn

Revenue range: $1–10bn

EBITDA range: $250–500M

EV/Revenue range: below 1.5x

EV/EBITDA range: 5x - 12x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Patterson Companies by Patient Square Capital are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: patterson companies

Acquirer: patient square capital

FAQ

What transaction does this page cover?

This page covers Patient Square Capital’s acquisition of 100% of Patterson Companies, an American company specialised in Medical Devices, in 2025.

How was the acquisition of Patterson Companies by Patient Square Capital valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the $1–10bn band, its EV/EBITDA multiple within the 5x - 12x range, and its EV/revenue multiple within the below 1.5x range. Exact figures are available to members.

What were Patterson Companies’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Patterson Companies generated annual revenue estimated in the $1–10bn range and EBITDA in the $250–500M bracket (FY 2024). Detailed financial figures are available to members.

How does the valuation of Patterson Companies compare to benchmarks in the Healthcare & Pharma sector?

The estimated multiple of 5x - 12x sits below the sector median of 14.5x recorded in 2025, indicating an attractive entry multiple for Patient Square Capital or reflecting specific complexities. The descriptive comparison is based on 15 transactions with available EV/EBITDA multiples from differences in size, growth, profitability that may affect comparability.

What sources support the information on this transaction?

Information on this transaction is sourced from the official corporate announcement published by the parties, corroborated by a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.